Form 4: OptiNose Executive Paul Spence Jr. Receives Stock Options and Restricted Stock Units

Paul Spence Jr., Chief Commercial Officer of OptiNose, Inc., was granted stock options and restricted stock units (RSUs) on February 28, 2024.

Summary

• Paul Spence Jr., the Chief Commercial Officer of OptiNose, Inc., received a grant of 252,675 restricted stock units (RSUs) on February 28, 2024.
• These RSUs vest over a four-year period, with 25% vesting on February 28, 2025, and the remainder vesting in equal quarterly installments.
• Full vesting is contingent upon continued service and may be accelerated if certain performance criteria related to OptiNose's net revenue and operating profit are met.
• Spence Jr. also received options to purchase 126,338 shares of common stock at an exercise price of $1.815 per share.
• These options also vest over a four-year period, with 25% vesting on February 28, 2025, and the remainder vesting in equal monthly installments, subject to continued service.

Sentiment

Score: 6

Explanation: The document is a routine disclosure of executive compensation. It's neutral in tone and doesn't contain any information that would significantly impact investor sentiment positively or negatively.

Positives

• The grants of RSUs and stock options align the executive's interests with those of the shareholders.
• The vesting schedules incentivize continued service and performance.

Risks

• The value of the RSUs and stock options is dependent on the future performance of OptiNose's stock.
• Failure to meet the performance criteria could result in unvested RSUs.

Future Outlook

The vesting of the RSUs is contingent on continued service and may be accelerated if certain performance criteria related to the net revenue and operating profit of OptiNose, Inc. are achieved.

Industry Context

Stock option and RSU grants are common practices in the pharmaceutical industry to incentivize and retain key executives.

Comparison to Industry Standards

• Executive compensation packages in the pharmaceutical industry typically include a mix of base salary, bonus, stock options, and restricted stock units.
• The vesting schedules and performance criteria are generally designed to align executive compensation with company performance and shareholder value creation.
• Comparing the size and terms of these grants to those of executives at similar-sized pharmaceutical companies would provide a more complete assessment of their competitiveness.

Stakeholder Impact

• The grants of RSUs and stock options could potentially dilute existing shareholders if the options are exercised and the RSUs vest.
• The vesting schedules incentivize the executive to contribute to the company's success, which could benefit all stakeholders.

Key Dates